Second-Line Medications and Toxicities in GVHD
April 30th 2024A medical expert delves into various aspects of second-line therapies, including dose reductions, potential adverse reactions, and the possibility of transfusions, all of which are important considerations when managing patients on second-line treatments.
Watch
Emerging Therapies for Chronic Graft-Versus-Host Disease
April 26th 2024This segment of the virtual tumor board presentation focuses on the clinical development and use of emerging therapies, specifically Belumosudil, for the management of chronic graft-versus-host disease (cGvHD) following hematopoietic stem cell transplantation.
Watch
TIVO-3: Tivozanib vs Sorafenib in Advanced Renal Cell Carcinoma
Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.
Watch
RCC: Treatment Goals in the Third-Line Setting
Focusing on VEGF TKIs available for the treatment of patients with metastatic renal cell carcinoma, the panel discusses the goals of therapy in the third-line setting.
Watch
Adverse Event Profile and Tolerability of Fruquintinib Based on FRESCO-2 Trial
April 25th 2024Arvind Dasari, MD, explores the adverse event profile of Fruquintinib, highlighting its apparent tolerability, while emphasizing the importance of gathering real-world data to further assess the adverse event profile of this medication in clinical practice.
Watch
FRESCO-2 Study Design Overview
April 25th 2024Medical professionals provide background on the FRESCO-2 trial, which compared Fruquintinib to placebo in patients with heavily pretreated metastatic colorectal cancer. The trial enrolled patients who had exhausted all standard treatment options, including cytotoxic chemotherapy, targeted therapies, anti-VEGF agents, and BRAF inhibitors for those with BRAF mutations.
Watch
Overall Survival and Progression Free Survival in the FRESCO-2 Trial
April 25th 2024Arvind Dasari, MD, examines the progression-free survival and overall survival data from the FRESCO-2 trial, comparing the results to the original FRESCO trial, and discussing the implications for the treatment of heavily pretreated metastatic colorectal cancer patients.
Watch
RESPONSE Trial and Hydroxyurea Resistance
April 24th 2024Dr. Kuykendall comments on the high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in the RESPONSE trial for hydroxyurea-resistant/intolerant PV, and how these efficacy findings inform his treatment choices.
Watch
Factors in Selecting Initial PV Therapy
April 24th 2024Dr. Kuykendall explains the factors he considers when deciding on initial therapy for advanced PV patients, including comorbidities, individual patient factors like age and symptoms, and weighing the risks and benefits of different treatment options.
Watch
Factors Considered for Initial Therapy in Myelofibrosis
April 24th 2024Dr. Bose shares his perspective on the factors he considers when deciding on initial therapy for myelofibrosis, including his approach to timing of treatment initiation and how splenomegaly influences his choice of JAK inhibitors.
Watch